Urofollitropin is a purified form of

follicle-stimulating hormone Follicle-stimulating hormone (FSH) is a gonadotropin, a glycoprotein polypeptide hormone. FSH is synthesized and secreted by the gonadotropic cells of the anterior pituitary gland and regulates the development, growth, puberty, pubertal maturat ...

(FSH) that is manufactured by extraction from human urine and then purified to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the

ovaries The ovary () is a gonad in the female reproductive system that produces ova; when released, an ovum travels through the fallopian tube/oviduct into the uterus. There is an ovary on the left and the right side of the body. The ovaries are endocr ...

. Given by

subcutaneous injection Subcutaneous administration is the insertion of medications beneath the skin either by injection or infusion. A subcutaneous injection is administered as a bolus (medicine), bolus into the subcutis, the layer of skin directly below the dermis and ...

, it is used in combination with

human chorionic gonadotropin Human chorionic gonadotropin (hCG) is a hormone for the maternal recognition of pregnancy produced by trophoblast cells that are surrounding a growing embryo (syncytiotrophoblast initially), which eventually forms the placenta after implantat ...

(hCG) to assist in

ovulation Ovulation is an important part of the menstrual cycle in female vertebrates where the egg cells are released from the ovaries as part of the ovarian cycle. In female humans ovulation typically occurs near the midpoint in the menstrual cycle and ...

and

fertility Fertility in colloquial terms refers the ability to have offspring. In demographic contexts, fertility refers to the actual production of offspring, rather than the physical capability to reproduce, which is termed fecundity. The fertility rate ...

.Drugs.com
Urofollitropin (Intramuscular route, Subcutaneous route, Injection route)
/ref> It is also used with ''in vitro'' fertilization methods. The dosage is adjusted to each individual's response. The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment. Bravelle sold in the United States from March 2014 through October 2015 is subject to a recall and refund by its maker, Ferring Pharmaceuticals, because certain batches of the medicine had a lower strength than stated.Enforcement Report - Week of October 21, 2015
Food and Drug Administration

References

External links

Bravelle
by Ferring Pharmaceuticals, Switzerland

by Institut Biochemique SA, Switzerland {{GnRH and gonadotropin receptor modulators Drugs developed by Schering-Plough Drugs developed by Merck & Co. Drugs developed by Merck Gonadotropin-releasing hormone and gonadotropins Human female endocrine system